Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The HBV Gray Zone: Patient and Physician Sharing Session #5

In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels.
Anna Christina L. dela Cruz, MD
Released: July 28, 2021

In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Anna Christina L. dela Cruz, MD

Associate Professor
Division of Digestive Diseases and Nutrition
Department of Internal Medicine
University of Kentucky
Lexington, Kentucky

Anna Christina L. dela Cruz, MD, has disclosed that she has received funds for research support from Novo Nordisk.

Program Medium

This program has been made available online.

Related Content

Review key slides on the interplay of COVID-19 and viral hepatitis and review expert strategies for managing chronic liver disease in the COVID-19 era

Released: January 10, 2022

Clinical Care Options (CCO) commentary by Dr. Dominique Braun on the results of the Swiss HCVree Trial: HCV testing, treatment, and counseling in MSM with HIV and HCV

Dominique Laurent Braun, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Limitations of the APASL guidelines and potential role of using HBcrAg for treatment candidacy and HCC screening, from Clinical Care Options (CCO)

Yasuhito Tanaka, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 3, 2022 Expired: January 2, 2023

Dr. Jean-Michel Pawlotsky: guidance from EASL on the treatment of patients with HBV and cirrhosis, from Clinical Care Options (CCO)

Jean-Michel Pawlotsky, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 20, 2021 Expired: December 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings